Brussels, 24 January 2021
– EuropaBio is pleased to announce that the next edition of EFIB, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title‘Next generation economies: Industrial biotechnology for a sustainable society’
, will take place 26-27 October 2022 in Vilnius, Lithuania
. The Forum will be hosted by the Lithuanian Biotechnology Association (LBTA) together with Go Vilnius – the city’s official business and tourism development agency.
Now in its 15th year, EFIB will be dedicated to the innovation and commercial delivery of industrial biotechnology and the bioeconomy. EFIB will include a pre-conference science symposium ’’Gene Editing – From Research To Industry’’, followed by two day Forum discussing how Industrial biotechnology contributes to transforming sectors and addresses consumer choices and needs.
‘After a successful 2021 in person edition, which discussed how our companies can help to deliver the EU Green Deal, we are exploring how industrial biotechnology advances contribute to the next generation economies and creating more sustainable societies. Lithuania is an outstanding location and a growing hotspot for Life Sciences in Europe, which makes it a perfect destination for our community to gather together and search for new synergies.’ said Dr Claire Skentelbery, Director General of EuropaBio.
The conference will network and showcase more than 500 delegates from the industry of all sizes, from start-ups with the next transformative technology to multi-national producers scaling up to meet global demand for sustainable and novel products across sectors. It will also bring together the community that enables the industry to deliver, including the researchers, policy makers, academia, regulators, global organisations and local leaders that build the framework for a sustainable society.
“EFIB 2022 pre-conference will reflect the great potential of gene editing technologies, like CRISPR Cas, for which Lithuania is widely known for, and will cover the successful stories how gene editing research outcomes were turned into successful applications with the remarkable impact on the future of the life sciences industry.“ Said Dr Monika Paule, CEO of CasZyme & LBTA Board Member.
For the first time in 2022, EFIB will host a post-conference meeting in the Permanent Representation of Lithuania to the EU in Brussels on 30 November, which will deliver the EFIB Vilnius Statement to policy makers at the heart of Europe.
The registration for the EFIB 2022 will be opened in March. For more information please visit our website and subscribe to our newsletter.
Are you interested in sponsorship opportunities?
EFIB offers an opportunity for sponsor organisations to achieve key objectives, including sector messaging and advocacy or products and services visibility. For more information please contact Dr Claire Skentelbery, Director General of EuropaBio (email@example.com